Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who to listen to? Message board sewage or doctors specializing in RCC? https://www.onclive.com/web-exclusives/nivolumabtivozanib-combo-shows-promise-in-mrcc
LOL. There's a whole new tone of trapped desperation now, as the upcoming nod from the FDA to submit the NDA for expedited processing after bringing the HR <1 will rocket this back to the $3.50 range in a matter of days.The trap sprung hard on them with that early announcement of the interim results. Love it. It's like the scene where Regan MacNeil is talking to Father Damien Karras
Logic says that longer progression free survival will obviously translate into longer overall survival, just as the interim P3 data illustrated. The HR is decreasing over time as the overall survival data is catching up with the progression free survival data. Trying to make nonsense out of common sense is disingenuous.
The remaining shorts are trapped and babbling BS. The smart shorts have all covered and moved on...look at the declining interest since the highs in April: https://old.nasdaq.com/symbol/aveo/short-interest Short interest at 9/13 ticked up a tiny amount to 17.2M shares after the HUGE move in share price on 9/9. The bulls are in charge.
Panicked shorts can only spew nonsense as the promising trials advance as well as the share price. How's that reverse split working for you shorts?? LOL. AVEO was IPO'd in 2010 and has never, repeat never, reverse split. How many micro-cap bios can say that? It's called toughing it out and remaining focused. The shorts' bets are done. Throw your tickets on the floor and move on. Adam Fuerstein doesn't even talk about AVEO anymore after he got smoked on his last blurb in April. And Clay's viagra prescription remains lapsed as he can't even find his johnson anymore.
This post from CirrusTrading on ST pretty much sums up AVEO: "One interesting tidbit is if you run the chart all the way back to 3/8/2010, you find there has never been a r/s. That's very unusual for a small bio and shows great strength and w/this news, there will never be one." A thoughtful and relevant post vs. the "turd" and "junk science" posts written here by trapped shorts constantly posting about a reverse split that's not coming.
This "turd" combined with BMY's Opdivo just blew the doors off on PFS in the Tinivo trial. Not bad for a junk drug. They'll likely move on a P3 now, and BMY will likely foot most of the bill. Sucks to be short on AVEO.
This "turd" is up 46% in less than 2 weeks from .65 compared to certain predictions of it dropping 85% to a dime. That's what I call LMAO.
60% gain in 7 trading days and it gives back 11% in consolidation and the shorts come out of the crevices. Wait until OPEX tomorrow and possibly another PR in the after hours or pre market on Monday. Stock prices don't go straight up. Don't fall for the bait getting thrown around by the cockroaches. It's the same bait they were throwing around last week promising a reverse split this past Monday. Their whole game plan is to throw out one contemptuous lie after another. There's a special place in hell for those who lie about a medicine that makes RCC sufferers' lives better.
Tuesday's 8K announcing the 180 day NASDAQ compliance extension is huge news for AVEO and closes the door on delisting and any reverse split. It solidifies the recovery that began a week and a half ago and refutes all the lies and nonsense that has been posted about the company. The vacating CFO's position is not actively being recruited because the buyout is in its final stage and Matthew Dallas' task has been completed. It was the sole reason of why he was hired and recruiting a new CFO would be a waste of time with the buyout imminent. Here is the link that comes up when you click on AVEO's "Join our team" employment button: https://careers-aveooncology.icims.com/jobs/login?back=intro&hashed=-435804896 Hmmm.
The ESMO conference at the end of the month will announce more positive data for the ongoing Tivo/Opdivo trial, as the CEO wouldn't have mentioned the results in the last webcast if the data is not going to be positive. EUSA will opt-in for Tivo 3 to expand their treatment lines for Fotivda from first line to second and third lines. The shorts are trapped and were caught off guard by the early announcement of the .99 HR for the Tivo-3 interim data. This is all common sense interpretation of what is happening right now with AVEO. This is Q3-Q4 2017 all over again, on steroids.
The AVEO bear trap is in full clamp down mode and the spring is way too strong for any extraction. Going to be a painful run for da bears as the greed for <.65 has led the pigs to slaughter. What a shame. Not.
Another bright green day on double the average volume. And shockingly,no reverse split. LOL.
There will be no reverse split Monday, as it was voted down by shareholders as stated in the 6/13/19 8K: "An amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, by a ratio of not less than 1-for-5 and not more than 1-for-15, and a proportionate reduction in the number of authorized shares of common stock, such ratio and the implementation and timing of the reverse stock split to be determined in the discretion of the Board, was not approved. This proposal required the approval of stockholders holding a majority of the outstanding shares of the Company’s common stock."
The reverse split is off the table and this past Thursday's 8K states the $25M milestone from Kirin has provided the minimum $5M stockholders' equity that will satisfy NASDQ compliance. Delisting is now effectively off the table. And my money's on EUSA ponying up the $20M milestone for the successful Tivo 3 data rights by the end of the month as well, further satisfying the compliance metrics. Matthew Dallas just hit a walk off homer in the 9th just before the trade deadline, LOL.
And there you have it.https://finance.yahoo.com/news/aveo-oncology-announces-updated-overall-103000502.html
Say goodbye to our #1 junk poster. AVEO will file NDA and get approval for Tivo in the US. Dr. Rini puts the final nail in the junk poster's constant bashing of AVEO. “These are the first data to demonstrate durable improvements in this highly refractory advanced kidney cancer population, including the post-immunotherapy setting, a predefined subset of the TIVO-3 trial,” said Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Director, Cleveland Clinic Genitourinary Cancer Program, and principal investigator of the TIVO-3 trial."
the EMA has removed Fotivda from its list of post-authorized medicines under additional review. I guess they've confirmed for the 2nd time that the drug isn't junk. https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring
The only junk here is a certain poster who uses the words "turd" and junk" in his contemptuous analysis.
Fortunately, the options chain matters and your opinion matters not.
Sure, that's why short interest is down 33% since April, its lowest level since the NDA delay announcement. https://www.nasdaq.com/symbol/aveo/short-interest
Shorts still clinging and ignoring the options chains are now floating aimlessly down the De Nile River in a boat full of holes. LOL. This will be epic as they scurry and disappear into the bowels of civilization.
Prelim O/S data represented only 50% last November. Combine that with the 34 patients remaining on treatment with Tivo vs only 9 remaining on Sora and the fact that 55% of patients were still responding to TIVO after 2 years of treatment, more mature O/S data will be favorable, hence the $1 call activity and trend change in SP. Or you can listen to a guy on this forum that says AVEO is a turd and headed to 10 cents. You make the call. Listen to the facts:
https://www.veracast.com/webcasts/bio/internationalconvention2019/56224292326.cfm?db=0.17215093315092567
The heavy volume of $1 call options directly refute your heavily opinionated short claims. Solid support in .70 range is in direct correlation with June 2017 levels leading up to CHMP's positive opinion. History likes to repeat itself.
Yeah, people accepting promotions and better deals is so unheard of.
Watch what happens in the next 27 days! .10 or $1.10? Talk to me on 9/27.
Wow! The shorts are blabbering nonsense like mental patients and claiming a reverse split is coming that was clearly just voted down by the shareholders. Looks like they're getting ansy with all that call option action now. They must be absolute hoots at the poker tables. LOL.
The "reality" of most of Cabo's patients are the dreams of an effective drug with manageable side effects like Tivo getting approved to make their lives better.
As the O/S data matures favorably with the Sora crossover effect outlined in detail, the HR will decreaase and the FDA will give the nod for the NDA submission. Tivo will gain U.S. approval and the current .65 - .70 price point will grow to $5 - $10 by the end of 2020. The process has been arduously long....welcome to the world of investing in pharmas. You mention EXEL. Their competing drug is riddled with horrible side effects and is like undergoing chemo.
Hard to say. If O/S is mature and HR decreases, it could easily hold $1+. If O/S data has not matured long enough and there's another delay, it could be at .50 - .55 If positive Ficlatuzamab news breaks on a Phase 3 pancreatic cancer trial start,it will be above $1. If they announce new partners for development of AV-380 and/or AV-353 with attached milestone payments, it could go to $2+ There are so many balls in the air now, it's impossible to answer your question.
Tivo3 trial met its primary endpoint, so another blatant lie posted on this thread from you know who. The immature O/S data influenced by the Sora crossovers caused a delay with O/S which will be rectified with the pending mature data readout. Then the NDA will be filed.Then the FDA will approve the drug.Then this will be a $9 stock. It's happening within 12-18 months.
Gearing up for another run into the $2-$3 range. All analysts concur.Not a Sell rating to be found. https://www.nasdaq.com/symbol/aveo/analyst-research
Another million plus shares purchased by Susquehanna Capital on Friday's 13F filing. https://fintel.io/sob/us/aveo For a company that "nobody's buying", it sure is interesting that 55% of the float is held by institutions,about the exact same ratio as Amazon.
The smart shorts should be starting to close out their positions moving forward.
No buyers?.LOL. Millenium Mgt just filed a 3.4 million share buy Form 13F If there were no buyers, there would be no support here.
https://fintel.io/sob/us/aveo
"HR will be below 1 in August. The difference will be (1) Sora early PD-1 converts dying, where Tivo doesn't have any early PD-1 converts, (2) Tivo's 24 non-PD1s on therapy either remaining on therapy or converting to a PD1 (Sora only has 7); (3) Tivo's 10 PD1s on therapy to Sora's 2; and (4) nearly all other patients being dead at that point." From Mesaboogie/S.T.
Q3 WILL BE PROFITABLE! $27M on the Q3 books already with more EUSA royalties to come...they paid AVEO $700K in Q2 royalties.That puts the delisting issue to bed. With the street picking up on this knowledge, we'll be >$1 by mid Sept anyway. I'd short it some more Harry.I picked up 25,000 more yesterday at .652
Hmmmm, really? AVEO trades an average 2.7 million shares per day at support. NEA, Vanguard, Citadel, Larson, Blue Mountain, State Street...the list goes on of recent AVEO buying. When will the lying stop??? If no one was buying, 2.7M shares a day would have had this at .10 like you claim. https://fintel.io/sob/us/aveo
And here's Adam F on AVEO:
Lies, lies, and more lies from Dirty Harry$AVEO +36% on positive CHMP opinion. Not sure how much tivo will be used but it’s a nice turnaround story.
— Adam Feuerstein ✡️ (@adamfeuerstein) June 23, 2017
Sure. Just wait for the 3rd quarter 10Q with $25M in revs on the books. There will likely be a buyout announcement by Nov 1st.
https://ih.advfn.com/stock-market/NASDAQ/aveo-pharmaceuticals-AVEO/stock-news/80448802/current-report-filing-8-k
"Upfront $25M payment within 30 days of the effective date" which was Aug 1st when the 8K was filed Item 1.01 Entry into a Material Definitive Agreement. Shorts will be scrambling to cover, hence a squeeze of epic proportions.
This is going to be an epic squeeze next quarter...just like Q3 was in 2017. Those who thought they missed the boat then have been given the same opportunity all over again. The market's like that. And there were boatloads of bashers spewing their BS all over the message boards leading up to Q3 2017. And Zacks had AVEO as a Strong Sell all year leading up to 6/23/17. Kirin just gave AVEO $25M. Is that a move they'd make if AVEO was on its way to BK like some here keep saying? Would they be wasting their time and money on AVEO if it was on the way out? And if Tivo3 was on the way to failure, would the largest shareholder(NEA/GEO4) be sitting around waiting to lose around $60M or would they have started liquidating Feb 1st after the NDA delay and share price setback? No, they bought more in April. Does one follow the money or does one follow guys who use "Junk" in every lying sentence they write?
Bye bye Harry. Good riddance.
Oh there will be when HR comes in <.1 at readout. Maybe you should watch this one more time. He(an RCC oncologist) pretty much refutes everything you say about the drug. It's really all you need to know about this subject and what's coming in Q4. https://vimeo.com/319964000
Do we believe Harry Crumb of IHub or Dr. Brian Rini of ASCO?
https://www.ascopost.com/videos/2019-genitourinary-cancers-symposium/brian-rini-on-the-tivo3-trial-on-tivozanib-vs-sorafenib/
The fact of the matter is Tivo works so well, AVEO was over confident in planning to file the NDA too soon. It was a blessing that the FDA stepped in and told them to slow down and get their complete data set together. Had they not done that and AVEO filed prematurely, a 2nd CRL was likely a given, and Harry would be right about .10 So this became a short's dream at the end of January. But the big money has not only remained and not sold a share, they added 4+million shares in April. Does that sound like a move NEA would make for shits and giggles or does that sound like a move that was made after more data(likely both PFS and O/S) was scrubbed in Feb for ASCO? And who swallowed up the additional 17M shares of the latest offering if NEA bought 4.3M of the 21.7 issued? If Harry hasn't covered by now, he is in for a world of pain moving forward.
It appears that the shorts have run out of gas in the mid to upper .60's The volume is picking up, and with it, so is the share price.
No, you're consistently incorrect on these baseless statements. You've been calling for .25 to bankruptcy forever. It's not happening. NEA won't let it.
Sept $1 calls selling like hotcakes Harry. Looks like your .50/.25/0 trajectory is wrong yet again. LOL.